Navigation Links
Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
Date:10/20/2008

in clinical quantities to support clinical trials; and cysteamine's ability to benefit NASH patients. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form S-1 that was declared effective on August 7, 2008; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on July 9, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Su
'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Provides Update of Product Programs
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
6. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
7. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
8. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
10. Critical Pharmaceuticals Enter Sustained Release hGH Arena
11. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Vista Partners announced today that it has ... "Company") and raised its twelve month target price to AUD ... is on track to enter clinical trials for its AMI ... The Company recently completed humanisation of its "first in class" ...
... of brand drug "copay coupon" promotions, which lure insured ... costs by $681 million in Missouri over the next ... to new research from Visante and released by the ... of these promotions by state and local government workers ...
Cached Medicine Technology:Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12 2Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $681 Million in Missouri 2
(Date:4/15/2014)... a decades-old medical mystery and in the process have ... infections, which kill about 1.5 million people a year. The ... amphotericin, an antifungal drug that has been in use for ... as toxic to human cells as it is to the ... new findings appears in Nature Chemical Biology . , ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide ... emotional behavior issues in other areas of the world, ... research that could lead to successful interventions. , ... the United Nations mentions that due to the HIV/AIDS ... Sub-Saharan African, children are at an increased risk for ...
(Date:4/14/2014)... IL A new study shows that moderate to ... increased risk of stroke, cancer and death. , Results ... moderate to severe obstructive sleep apnea were four times ... four times more likely to have a stroke (HR ... cancer (HR = 3.4), and 2.5 times more likely ...
(Date:4/14/2014)... involving serious youth offenders, the answer to one open-ended question ... "How long do you think you,ll live?", According to the ... time., Author Dr. Alex Piquero said the study found those ... offend at very high rates and commit more serious offenses, ... in life offend much less., "In a lot of distressed ...
(Date:4/14/2014)... Depression can hit young fathers hard -- with symptoms increasing ... children,s lives, a new Northwestern Medicine study has found. , ... first five years of fatherhood for these young men, who ... whom lived in the same home as their children. The ... journal Pediatrics . , This study is the first ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2
... Some patients with large tumors on their larynx can ... surgery to remove the voice box. A new study ... a single round of chemotherapy could identify those patients most ... have excluded these patients because their tumors are so large. ...
... DC (June 25, 2009) Evidence suggests that outcomes in ... means that research into quality improvement (QI) in clinical care ... Now a study in the journal Medical Care Research ... and practical improvements in QI effectiveness studies could make these ...
... FUNCTIONING TISSUE VIOLATES MEDICAL ETHICS, HUMAN RIGHTS OF BABY BOYS ... NEW YORK, June 25 Parents, pediatricians and health and ... and its website -- www.intactamerica.org -- ... campaign argues that painful and medically unnecessary surgery to remove ...
... in German . , Providing reliable ... and labor-intensive molecular-biological procedures. Established methods are particularly hard ... very low, for example during a phase of therapy. ... micro-pumps without movable parts, scientists from the Fraunhofer Institute ...
... June 25 The YWCA USA and many of its 300 ... for Disease Control and Prevention in marking National HIV Testing Day ... to raise public awareness about the fact that one in five ... as a consequence, can unknowingly spread the deadly virus to others. ...
... June 25 The Infectious Disease Research ... M.J. Murdock Charitable Trust. This new funding will support IDRI,s efforts ... identify new drugs to treat it. , ... the air and can be hard to avoid. A seemingly insignificant ...
Cached Medicine News:Health News:U-M study finds voice box can be preserved, even with the largest cancers 2Health News:Health care outcome boost needs better studies 2Health News:Health care outcome boost needs better studies 3Health News:Health care outcome boost needs better studies 4Health News:Intact America Launches Campaign to Change How America Thinks About Male Circumcision 2Health News:Intact America Launches Campaign to Change How America Thinks About Male Circumcision 3Health News:Intact America Launches Campaign to Change How America Thinks About Male Circumcision 4Health News:Virus filters for medical diagnosis 2Health News:YWCAs to Mark National HIV Testing Day on June 27 2Health News:IDRI Awarded $314,500 Grant From Murdock Trust to Expand TB Drug Discovery Program 2Health News:IDRI Awarded $314,500 Grant From Murdock Trust to Expand TB Drug Discovery Program 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: